SUBSCRIBE
SUBSCRIBE
Kate Goodwin

Kate Goodwin

Contributing Writer | News & Features

Kate Goodwin hails from a background primarily in marketing. A passion for health sciences and writing led her to the biopharma news world, and she’s never looked back. She’s been writing for BioSpace for more than two years with a focus on cutting edge research, Alzheimer’s disease and pediatrics. Her free time is filled by her husband, children, Beagles, books, crochet and creative writing. She can be reached at kate.goodwin@biospace.com.

Amgen sign at its headquarters in Thousand Oaks, California, USA.
Drug Development
Amgen’s Weight-Loss Drug Candidate Shows Promise in Early Data
Phase I results published Monday suggest Amgen’s investigational weight-loss drug MariTide produces longer-lasting effects than GLP-1s currently on the market.
February 5, 2024
 · 
1 min read
 · 
Kate Goodwin
Pictured: A MRI brain scan background, magnetic us
Drug Development
5 Alzheimer’s Data Readouts to Watch in 2024
With one disease-modifying therapy already reaching patients and another expected to soon, several biopharma companies anticipate key data for novel assets in the coming 12 months.
February 2, 2024
 · 
4 min read
 · 
Kate Goodwin
Pictured: Bristol Myers Squibb in NJ/iStock, arlut
Business
BMS Tops Q4 Estimates, Looks to New Products and M&A with Exclusivity Loss
The pharma Friday reported in-line and new product revenue growth of 9%, bringing in $9.8 billion for the fourth quarter of 2023. Eliquis and Opdivo remain top sellers but BMS is facing the loss of exclusivity.
February 2, 2024
 · 
2 min read
 · 
Kate Goodwin
Pictured: Roche tower in Basel, Switzerland
Business
Roche’s 2024 Strategy Seeks to Fight Low Growth with Pipeline Cuts, M&A
The Swiss pharma on Thursday projected mid-single-digit sales growth for 2024, culling eight assets and looking to acquisitions and collaborations for de-risked assets with “significant potential.”
February 1, 2024
 · 
2 min read
 · 
Kate Goodwin
Pictured: Biogen's headquarters in Cambridge, Massachusetts
Biogen Axes Alzheimer’s Drug Aduhelm to Focus on Leqembi in Resource Realignment
The company on Wednesday said it is ending all development and commercialization activity for its Alzheimer’s disease drug Aduhelm to focus on Leqembi with partner Eisai.
January 31, 2024
 · 
2 min read
 · 
Kate Goodwin
Pictured: Pfizer office at its South San Francisco
Business
Pfizer Gets Q4 Earnings Beat on Smaller Than Expected COVID-19 Sales Decline
Excluding its COVID-19-products Comirnaty and Paxlovid, Pfizer’s revenue in the fourth quarter of 2023 grew 8%. The company projects full-year revenue in 2024 to remain about flat.
January 30, 2024
 · 
2 min read
 · 
Kate Goodwin
Facade of the FDA's office in Maryland
Policy
Decoding the FDA’s Classifications for a Faster Path to Approval
The FDA’s myriad acronyms—and the differences between them—can be perplexing. BioSpace looks at the unique advantages of certain regulatory classifications for drug developers.
January 26, 2024
 · 
4 min read
 · 
Kate Goodwin
Pictured: Lonza Facility in TX/iStock, JHVEPhoto
Business
Lonza Projects Flat Sales for 2024 as CDMOs Look to Recover from 2023
While the company expects sales growth to be flat this year, Lonza’s shares jumped around 14% Friday morning after reporting full-year 2023 sales of $7.75 billion, which was 3% above the consensus.
January 26, 2024
 · 
1 min read
 · 
Kate Goodwin
Pictured: Delayed Stamp/iStock, Olivier Le Moal
Policy
FDA Misses PDUFA Date for Liquidia’s NDA for Inhaled Blood Pressure Drug
After missing its Jan. 24 PDUFA date, the regulator has extended its review period but has not issued a new decision timeframe or requested additional data, Liquidia announced Thursday.
January 25, 2024
 · 
1 min read
 · 
Kate Goodwin
Pictured: J&J's office in Madrid, Spain
Business
J&J Beats Q4 Expectations, Reports $21.4B in Revenue as Faces Patent Cliff
Johnson & Johnson exceeded fourth-quarter earnings estimates, reporting nearly $21.4 billion in revenue, as its pharma business faces a patent cliff with Stelara competition entering the market.
January 23, 2024
 · 
2 min read
 · 
Kate Goodwin
Pictured: Illustration of a gloved hand holding tw
What’s Next for CRISPR?
Following the December and January approvals of Vertex Pharmaceuticals and CRISPR Therapeutics’ Casgevy, analysts believe another CRISPR approval is unlikely in the near future.
January 23, 2024
 · 
5 min read
 · 
Kate Goodwin
Pictured: SPAC Symbol/iStock, Dzmitry Dzemidovich
Deals
Cormorant Launches Second SPAC Following MoonLake Deal with $100M IPO
The blank check company Thursday filed with the SEC for the initial public offering. While a specific business for Helix Acquisition Corp. II has not yet been identified, the fund will target biotech.
January 19, 2024
 · 
2 min read
 · 
Kate Goodwin
Pictured: Facade of Novartis building in Switzerland
Drug Development
Novartis Ends Phase III Peanut Allergy Trial in Another Flop for Potential Xolair Successor
The Swiss pharma’s Phase III trial of ligelizumab in patients with peanut allergies has been terminated, according to a ClinicalTrials.gov update on Tuesday.
January 18, 2024
 · 
1 min read
 · 
Kate Goodwin
Pictured: Roche Diagnostics building in California
Drug Development
Roche Reports Phase III TIGIT Win at ASCO Gastro Cancer Meeting
When combined with Tecentriq and chemotherapy, tiroagolumab increased median survival to 15.7 months compared to 11.1 months for patients with esophageal squamous cell carcinoma on chemo alone.
January 17, 2024
 · 
2 min read
 · 
Kate Goodwin
Sign outside BioNTech's building in Germany
Business
BioNTech Continues to Build Pipeline with First Deal of 2024
The German biotech is dropping $20 million upfront on two preclinical monoclonal antibodies for undisclosed targets developed by WuXi Biologics.
January 11, 2024
 · 
2 min read
 · 
Kate Goodwin
Load More